PATENT CLAIM ANALYSIS

Application Number: 15945011
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "138100"]

Abstract:
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

Claim (Index 1):
An antibody that binds human PD-L1 (SEQ ID NO: 1) and human TIM-3 (SEQ ID NO: 2) comprising:\n a) a first heavy chain (HC) comprising the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 19, and SEQ ID NO: 22, b) a first light chain (LC) comprising the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 27, c) a second HC comprising the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 23, and SEQ ID NO: 26, d) a second LC comprising the amino acid sequences of SEQ ID NO: 10 and SEQ ID NO: 28; and wherein, the first LC forms an inter-chain disulfide bond with the first HC, the second LC forms an inter-chain disulfide bond with the second HC, and the first HC forms two inter-chain disulfide bonds with the second HC, and the first HC and second HC are human IgG1 isotype.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 91.0
- Lexical Diversity: 1.2069
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15239959', '15232026', '16064727', '15005042', '14709514']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7692628159069643
- 35 USC 102 Novelty (BERT): 0.5226253727438112
- Combined Prediction Score: 0.7445990715906491
- Mean Citation Score: 328.78834399999994
- Max Citation Score: 344.3392
- Similarity Product: 280.0013458484649

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test